Back to discover
Drug

Furosemide

Established medicine
ClassSodium-(potassium)-chloride cotransporter 2 inhibitorResearchActive indication expansion
Also known as Disal, Frusemide, Furoscix, Lasix+6 more

Disal, Frusemide, Furoscix, Lasix, Lo-Aqua, Salix - substance, Furosemid, Furosemida, Furosemidu, Furosemidum.

RxNorm4603ChEMBLCHEMBL35ATCC03CA01UNII7LXU5N7ZO5
1
Research papers
29
Active clinical trials
Solute carrier family 12 member 1
Primary target
32
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Vasodilatation or Loop-Diuretics for Initial Treatment of Pulmonary Congestion Due to Acute Heart Failure - A Randomized Placebo-Controlled Trial

Clinical trial2026-10-23Results expected Q2 2027 · ClinicalTrials.gov

Supplemental approval: FUROSEMIDE (ANDA070433)

Regulatory2026-10-16FDA

"Comparison of Furosemide Versus Albumin Plus Furosemide in Increasing Urine Output in Critically Ill Patients: A Double-Blind Randomized Clinical Trial"

Clinical trial2026-09-30Primary completion · ClinicalTrials.gov

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Clinical trial2026-09-11Results expected Q2 2027 · ClinicalTrials.gov

Salt-Sensitivity and Immunity Cell Activation

Clinical trial2026-09-01Primary completion · ClinicalTrials.gov

The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic

Clinical trial2026-08-05Status changed to Completed · ClinicalTrials.gov

Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function

Clinical trial2026-08-04Status changed to Completed · ClinicalTrials.gov

Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial

Clinical trial2026-07-26Primary completion · ClinicalTrials.gov

Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)

Regulatory2026-07-23FDA

Marketing authorisation: Bopediat (EMA)

Regulatory2026-05-29EMA

Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)

Regulatory2025-12-22FDA

Diuretic strategies in patients with acute decompensated heart failure.

Research2011-03-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Furosemide
Aliases & brands
DisalFrusemideFuroscixLasixLo-AquaSalix - substanceFurosemidFurosemidaFurosemiduFurosemidum
RxNorm CUI
4603
ChEMBL ID
CHEMBL35
ATC codes
C03CA01
UNII
7LXU5N7ZO5
Primary mechanism
Sodium-(potassium)-chloride cotransporter 2 inhibitor
Regulatory jurisdictions
fdaema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Solute carrier family 12 member 1
SLC12A1 · Q13621
INHIBITORSodium-(potassium)-chloride cotransporter 2 inhibitor

Regulatory timeline

32 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Approval / market entry confirmed across FDA and EMA (2025-03-06 → 2026-10-16)
Earliest approval on record (generic/biosimilar)
1987-04-22
Latest approval
2026-10-16
Authorities
FDA · EMA
Total events
32
fdaU.S. Food and Drug Administration· 31 events
2026-10-16Supplemental approvalMulti-authority
Supplemental approval: FUROSEMIDE (ANDA070433)
Evidence ↗
2026-07-23Indication expansionMulti-authority
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
Evidence ↗
2025-12-22Indication expansionMulti-authority
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
Evidence ↗
emaEuropean Medicines Agency· 1 event
2026-05-29Original application approvalMulti-authority
Marketing authorisation: Bopediat (EMA)
Indication: Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in… Show full indication

Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

175 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
175
registered trials across all phases
LATEST COMPLETION 2026
29
Active studies
24
Recruiting
115
Late-stage (III+)
94
Completed
52
Discontinued
PHASE DISTRIBUTIONn = 175
Early Phase 17Phase 127Phase 1 / 27Phase 219Phase 2 / 35Phase 330Phase 442Phase N / A38

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury (FST-LIBERATE)

RecruitingPH IVChiang Mai Universityn=802028

Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study

RecruitingPH IVUniversity of Delawaren=1202028

Optimizing Preeclampsia Postpartum With Point-of-Care Ultrasound: A Pilot Prospective Cohort Study

Not yet recruitingPH IVUniversity of California, Irvinen=962028

Goal Directed Fluid Removal With Furosemide in Intensive Care Patients With Fluid Overload - A Randomised, Blinded, Placebo-controlled Trial (GODIF).

RecruitingPH IVKey trialMorten H. Bestlen=1,0002028

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

RecruitingPH IVLakeland Regional Health Systems, Inc.n=6002027

Recent completions

Trials that read out recently, adding to the completed evidence base.

Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function

CompletedN/AKing Chulalongkorn Memorial Hospitaln=3602026

A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants

CompletedPH IMerck Sharp & Dohme LLCn=412026

The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic

CompletedN/AGulhane Training and Research Hospitaln=1212026

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Medium Sized Renal Stones

CompletedN/AKey trialAin Shams Universityn=2,0002025

Transporter Profiling Study for P-glycoprotein 1 (P-gp), Organic Anion Transporter 1 (OAT1), Organic Anion Transporter 3 (OAT3), Organic Cation Transporter 2 (OCT2), Multidrug and Toxin Extrusion Protein 1 (MATE1), Multidrug and Toxin Extrusion Protein 2-K (MATE2-K), Organic Anion Transporting Polypeptide 1B1 (OATP1B1), Organic Anion Transporting Polypeptide 1B3 (OATP1B3) and Breast Cancer Resistance Protein (BCRP) in Healthy Subjects and in Patients With Stage 4 (F4) Liver Fibrosis / Cirrhosis.

CompletedN/ABoehringer Ingelheimn=282024

The Effect of Zongertinib on the Pharmacokinetics of Dabigatran (Part 1) and Rosuvastatin, Metformin and Furosemide Administered as a Cocktail (Part 2) in Healthy Male Subjects (a 2-part, Open-label, 2-period, Fixed-sequence Cross-over Trial)

CompletedPH IBoehringer Ingelheimn=322024

Research activity

1 paper

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Diuretic strategies in patients with acute decompensated heart failure.

The New England journal of medicine · 2011 · 1,106 cites
Recent papers

Diuretic strategies in patients with acute decompensated heart failure.

The New England journal of medicine · 2011 · 1,106 cites
Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Anstrom KJ1
  • Bart BA1
  • Braunwald E1
  • Bull DA1
  • Chen HH1
  • Deswal A1
  • Felker GM1
  • Givertz MM1
Leading institutions
free-text, unnormalised
  • Duke University School of Medicine and Duke Heart Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.